Abstract
Background
There is yet no gold standard for the diagnosis of acute-onset autoimmune hepatitis (A-AIH), especially histologically acute AIH. As a result, long-term observation of A-AIH has been difficult and the nature is not well known. We retrospectively analyzed the clinicopathological features of A-AIH over a long prospective follow-up period.
Methods
Clinical, biochemical, immunological and pathological features of 30 patients (21 female, mean age 55.1 ± 13.1 years) with non-severe A-AIH “without signs of clinical and radiological chronicity” admitted to a community hospital between 2001 and 2015 who were prospectively followed for more than 2 years were analyzed retrospectively.
Results
Liver histology of 45% showed acute and 55% chronic hepatitis. Mean age was older, prothrombin time activity was higher, AIH scores before treatment were lower in histologically acute hepatitis than histologically chronic hepatitis significantly. Liver fibrosis was not coarse, but delicate with severe activity in most patients showing chronic hepatitis defined by our strict criteria. Median (range) follow-up period was 6.9 (2.1–16.2) years. Six (20%) patients experienced episode of relapses. All were alive at the last follow-up point. Corticosteroid was continued at 2.5–5 mg/day until the study end point without serious side effects in most patients. Serial change of alanine aminotransferase levels, immunoglobulin G levels and anti-nuclear antibody titers did not show statistical difference between histologically acute and chronic hepatitis.
Conclusion
Rapid progression of fibrosis could occur in A-AIH. Treatment response and long-term prognosis were good, and not different between patients with histologically acute and chronic hepatitis.
Similar content being viewed by others
Abbreviations
- AIH:
-
Autoimmune hepatitis
- A-AIH:
-
Acute-onset autoimmune hepatitis
- ALT:
-
Alanine aminotransferase
- IgG:
-
Immunoglobulin G
- ANA:
-
Anti-nuclear antibody
- CS:
-
Corticosteroid
References
Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21:866–871
Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci 2013;58:897–914
Fujiwara K, Yasui S, Yokosuka O. Autoimmune acute liver failure: the emerging etiology for acute liver failure (review). Hepatol Int 2013;7:335–346
Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H, Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011;46:1136–1141
Stravitz RT, Lefkowitch JH, Fontana RJ, Acute Liver Failure Study Group, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011;53:517–526
Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–938
Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25:263–270
Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004;28:471–478
Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59:246–249
Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute onset autoimmune hepatitis. J Gastroenterol 2008;43:951–958
Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011;46:378–390
Fujiwara K, Nakano M, Yasui S, Okitsu K, Yonemitsu Y, Yokosuka O. Advanced histology and impaired liver regeneration are associated with disease severity in acute onset autoimmune hepatitis. Histopathology 2011;58:693–704
Fujiwara K, Yasui S, Tawada A, Fukuda Y, Nakano M, Yokosuka O. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute onset autoimmune hepatitis. Liver Int 2011;31:1013–1020
Hennes EM, Zeniya M, Czaja AJ, International Autoimmune Hepatitis Group, et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology 2008;48:169–176
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–1520
Yasui S, Fujiwara K, Okitsu K, Yonemitsu Y, Ito H, Yokosuka O. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res 2012;42:42–50
Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during peg-interferon-alfa 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis 2011;43:666–667
Fujiwara K, Ohtsuka M, Yokosuka O. Radiologic and histologic heterogeneity in a case of autoimmune acute liver failure. Clin Gastroenterol Hepatol 2014;12:e19–e20
Fujiwara K, Fukuda Y, Seza K, et al. High level of persistent liver injury is one of clinical characteristics in treatment-naïve acute onset autoimmune hepatitis: experience in a community hospital. J Hepatobiliary Pancreat Sci 2016;23:174–180
Yasui S, Fujiwara K, Tawada A, Fukuda Y, Nakano M, Yokosuka O. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis. Dig Dis Sci 2011;56:3638–3647
Fujiwara K, Yasui S, Nakano M, et al. Severe and fulminant hepatitis of indeterminate etiology in a Japanese center. Hepatol Res 2015;45:E141–E149
Scheuer PJ, Maggi G. Hepatic fibrosis and collapse: histological distinction by orcein staining. Histopathology 1980;4:487–490
Horiuchi R, Uchida T, Karasawa T, Shikata T. Diagnostic significance of elastic fibers in liver diseases. Kanzo 1985;31:1315–1323
Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute onset autoimmune hepatitis. Hepatology 2011;54:371–372
Yoshizawa K, Matsumoto A, Ichijo T, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 2012;56:668–676
Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507–515
Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011;140:1980–1989
Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304:5–9
Muratori P, Granito A, Quarneti C, et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009;50:1210–1218
Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48:863–870
Acknowledgements
We are indebted to all our colleagues at our liver units who cared for the patients described herein. We thank Nobuyuki Moriya (Chiba Medical Center) for help in the extraction of old data.
Author information
Authors and Affiliations
Contributions
KF designed and performed the research, analyzed the clinical data and wrote the manuscript. KF, YF, KS, MS, SY, OY and NK contributed to the clinical aspects. KF and MN reviewed the histopathological changes. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Keiichi Fujiwara, Yoshihiro Fukuda, Katsushi Seza, Masaya Saito, Shin Yasui, Masayuki Nakano, Osamu Yokosuka and Naoya Kato declare that they have no conflict of interest.
Ethical approval
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent
Informed consent was obtained from all patients for being included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
12072_2018_9848_MOESM1_ESM.tiff
Supporting Figure 1. Serial changes of ANA titers of histologically acute (a) and chronic (b) AIH patients after the start of treatment. ANA, anti-nuclear antibody. (TIFF 1521 kb)
Rights and permissions
About this article
Cite this article
Fujiwara, K., Fukuda, Y., Seza, K. et al. Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitis. Hepatol Int 12, 191–199 (2018). https://doi.org/10.1007/s12072-018-9848-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-018-9848-z